Tallac Therapeutics
Burlingame, US · Founded 2018 · 5 known investors
Tallac Therapeutics is a clinical-stage biopharmaceutical company developing oligonucleotide-based antibody conjugates (TRAAC candidates) designed to deliver immune-activating agents to tumor microenvironments for oncology indications. The company has two programs currently in clinical trials.
Founders & leadership
Tallac Therapeutics was founded in 2018 by Hong Wan.
HW
Hong WaninPresident, Chief Executive Officer and Co-Founder
Board
RG
Ran GengBoard director
MC
Michael CarusiBoard director
IC
Isaac ChengBoard director
CB
Christine BrennanBoard director
CG
Corey GoodmanBoard director
JP
Jaume PonsBoard director
Investors · 5
Reported raises · per SEC filings
Form D private placements$61.6M disclosed across 1 round · 2020
▶$61.6MraisedJul 2021 · 12 investors · Other Health CareRule 506(b)
▶$61.6MraisedJul 2021 · 12 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Ran GengDirector
- Michael CarusiDirector
- Isaac ChengDirector
- Christine BrennanDirector
- Corey GoodmanDirector
- Hong WanExecutive Officer, Director
- Jaume PonsDirector
- Offering amount
- $61.6M
- Amount sold
- $61.6M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlapDialectic Therapeutics15 shared keywordsDialectic Therapeutics is a clinical-stage biotechnology company developing anti-cancer drugs using its Antiapoptotic Protein Targeted Degradation (APTaD) platform, which induces cancer cells to degrade proteins such as BCL-XL. Its lead candidate, DT2216, is in Phase 1/2 trials for fibrolamellar carcinoma and platinum-resistant ovarian cancer.
Relay13 shared keywordsRelay Therapeutics develops the Dynamo platform, which applies motion-based drug design principles to discover therapeutic drugs by integrating protein dynamics simulations with experimental and computational techniques. The platform serves pharmaceutical and biotech researchers seeking to accelerate drug discovery across multiple phases of development.
Solu12 shared keywordsSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
Trisaluslifesci10 shared keywordsTriSalus develops a therapeutic platform combining its Pressure-Enabled Drug Delivery (PEDD) method with immune-activating therapies to overcome intratumoral pressure and immunosuppression that limit treatment of liver and pancreatic tumors. The platform is designed to be used alongside systemic immunotherapies such as checkpoint inhibitors for cancer patients.
Companies competing with Tallac Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Tallac Therapeutics do?
- Tallac Therapeutics is a clinical-stage biopharmaceutical company developing oligonucleotide-based antibody conjugates (TRAAC candidates) designed to deliver immune-activating agents to tumor microenvironments for oncology indications. The company has two programs currently in clinical trials.
- Who founded Tallac Therapeutics?
- Tallac Therapeutics was founded by Hong Wan in 2018.
- Who are Tallac Therapeutics's investors?
- Tallac Therapeutics's investors include Lightstone Ventures, MRL Ventures Fund, venBio Partners, Matrix Partners China, venBio Global Strategic.
- How much funding has Tallac Therapeutics raised?
- Tallac Therapeutics has disclosed $61.6M raised across 1 round.
- Where is Tallac Therapeutics headquartered?
- Tallac Therapeutics is headquartered in Burlingame, US.